Stephens downgraded Avid Bioservices (CDMO) to Equal Weight from Overweight with a price target of $12.50, up from $12, after Avid filed its merger proxy associated with GHO/Ampersand’s proposed acquisition. It seems like this deal is likely to go through as proposed, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDMO:
- Understanding Avid Bioservices’ (CDMO) Acquisition: Risks and Opportunities
- Is CDMO a Buy, Before Earnings?
- Avid Bioservices downgraded to Hold from Buy at Craig-Hallum
- Avid Bioservices to be Acquired in $1.1 Billion Deal
- Avid Bioservices downgraded to Sector Perform from Outperform at RBC Capital